Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2009-11-30
pubmed:abstractText
The discrimination between well-differentiated liposarcomas/atypical lipomatous tumors and lipomas can be diagnostically challenging at the histological level. However, cytogenetic identification of ring and giant rod chromosomes supports the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumor. These abnormal chromosomes are mainly composed of amplified genomic sequences derived from chromosome 12q13-15, and contain several genes, including MDM2, CDK4 (SAS), TSPAN31, HMGA2, and others. MDM2 is consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors, and up to 25% in other sarcomas. As part of a large genomic study of lipomatous neoplasms, we initially found CPM to be consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors. To further explore this initial finding, we investigated the copy number status of MDM2 and CPM by fluorescent in situ hybridization (FISH) on a series of 138 tumors and 17 normal tissues, including 32 well-differentiated liposarcoma/atypical lipomatous tumors, 63 lipomas, 11 pleomorphic lipomas, 2 lipoblastomas, 30 other tumors and 17 normal fat samples. All 32 well-differentiated liposarcoma/atypical lipomatous tumors showed amplification of MDM2 and CPM, usually >20 copies per cell. The other tumors lacked MDM2 and/or CPM amplification. Chromogenic in situ hybridization confirmed the above results on a subset of these tumors (n=27). These findings suggest that identification of CPM amplification could be used as an alternative diagnostic tool for the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1530-0285
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1541-7
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19820690-Cell Differentiation, pubmed-meshheading:19820690-Comparative Genomic Hybridization, pubmed-meshheading:19820690-Diagnosis, Differential, pubmed-meshheading:19820690-GPI-Linked Proteins, pubmed-meshheading:19820690-Gene Amplification, pubmed-meshheading:19820690-Gene Dosage, pubmed-meshheading:19820690-Gene Expression Regulation, Enzymologic, pubmed-meshheading:19820690-Gene Expression Regulation, Neoplastic, pubmed-meshheading:19820690-Genetic Testing, pubmed-meshheading:19820690-Humans, pubmed-meshheading:19820690-In Situ Hybridization, Fluorescence, pubmed-meshheading:19820690-Lipoma, pubmed-meshheading:19820690-Liposarcoma, pubmed-meshheading:19820690-Metalloendopeptidases, pubmed-meshheading:19820690-Predictive Value of Tests, pubmed-meshheading:19820690-Proto-Oncogene Proteins c-mdm2, pubmed-meshheading:19820690-Tumor Markers, Biological
pubmed:year
2009
pubmed:articleTitle
Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma.
pubmed:affiliation
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't